Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ludmila Bourková"'
Autor:
Jitka Malčíková, Iveta Valášková, Ludmila Bourková, Katerina Stano-Kozubik, Jana Šmardová, Marek Borsky, Hana Skuhrová Francová, Šárka Pospíšilová, Martin Trbušek, Jana Kotašková, Michael Doubek, Viera Hrabčáková, Yvona Brychtová, Jiri Mayer, Boris Tichy
Publikováno v:
Cancer Genetics and Cytogenetics. 189:53-58
B-cell chronic lymphocytic leukemia (CLL) is an incurable disease with a highly variable clinical course. A proportion of patients eventually progress to a higher stage of malignancy. A recent association has been observed between the presence of abe
Autor:
J. Vinklárková, Doubek M, Daniela Zackova, Martin Klabusay, Tomas Buchler, Alexandra Oltová, Jiri Adler, Jiri Mayer, E. Janovská, Jiri Vorlicek, Eva Krahulcová, Karel Indrak, Edgar Faber, Ladislav Dušek, Petr Kuglík, Korístek Z, Miroslav Penka, Roman Hájek, Iveta Mareschová, Ludmila Bourková
Publikováno v:
Medical Oncology. 20:69-76
Interleukin-2 (IL-2) is able to generate nonspecific cytotoxic effectors from hematopoietic precursors. We evaluated the feasibility and efficacy of chronic myeloid leukemia (CML) treatment with autologous hematopoietic stem cell transplantation (HSC
Publikováno v:
International journal of hematology. 100(5)
BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribu
Autor:
Jaroslav Michálek, Libor Hanák, Romana Musilová, Ludmila Bourková, Tomas Buchler, Alena Buliková, Roman Hájek, Lucie Kovářová, Darina Očadlíková
Anticancer immunotherapy using dendritic cell-based vaccines is a strategy aimed at the induction and maintenance of immune responses against cancer cells. Clinical applications of dendritic cells (DCs) require stringent adherence to Good Manufacturi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75e65d632836884c00268e93916573b9
http://hdl.handle.net/11585/114008
http://hdl.handle.net/11585/114008
Autor:
Roman, Hájek, Daniela, Zácková, Tomás, Büchler, Miroslav, Penka, Eva, Krahulcová, Zdenĕk, Korístek, Jaroslava, Vinklárková, Jiri, Adler, Eva, Janovská, Karel, Indrák, Edgar, Faber, Michal, Doubek, Martin, Klabusay, Alexandra, Oltová, Petr, Kuglík, Ludmila, Bourková, Ladislav, Dusek, Iveta, Mareschová, Jiri, Mayer, Jiri, Vorlícek
Publikováno v:
Medical oncology (Northwood, London, England). 20(1)
Interleukin-2 (IL-2) is able to generate nonspecific cytotoxic effectors from hematopoietic precursors. We evaluated the feasibility and efficacy of chronic myeloid leukemia (CML) treatment with autologous hematopoietic stem cell transplantation (HSC
Autor:
Jana Vinklárková, Miroslav Penka, Ladislav Dušek, Martin Klabusay, Michael Doubek, D. Dvořáková, Roman Hájek, Jiří Adler, Ludmila Bourková, Tomas Buchler, Jiří Mayer, E. Janovská, Zdeněk Adam, Zdeněk Kořístek, Jiří Vorlíček
Publikováno v:
Acta medica Austriaca. 29(2)
BACKGROUND: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T-cell and natural killer (NK) mediated anti-tumou